FRAZER, Pa., Feb. 4 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that Sarma P. Duddu, Ph.D., has been appointed as General Manager and Vice President of Drug Delivery Technologies of CIMA LABS, Inc. In this role, Dr. Duddu will lead all aspects of the Cephalon drug delivery business at CIMA, its wholly owned drug delivery subsidiary located in suburban Minnesota.
In his new role, Dr. Duddu will be a member of the Cephalon Technical Operations leadership team and will report directly to Peter E. Grebow, Ph.D., Executive Vice President of Worldwide Technical Operations.
"We are pleased with the strong record of successful drug development that Sarma brings to our organization," said Peter Grebow, Ph.D., Executive Vice President Worldwide Technical Operations. "His extensive experience in drug delivery and previous leadership roles in R&D, product development and new product research make him well qualified to not only lead, but to strengthen and grow our drug delivery business."
Dr. Duddu has more than 15 years of pharmaceutical experience and has been involved in all aspects of the drug delivery business. Most recently, he held the position of vice president of pharmaceutical development at Nektar Therapeutics (formerly Inhale Therapeutic Systems) based in San Carlos, CA. Previously at Nektar, Dr. Duddu held key management positions in product development, R&D operations, corporate development and strategy, as well as new product research. Prior to Nektar, he worked at SmithKline Beecham Pharmaceuticals in King of Prussia, PA, where he focused in the areas of pharmaceutical technology formulation sciences and product development.
Dr. Duddu earned a Ph.D. in Pharmaceutics from the
About CIMA LABS INC.
CIMA LABS INC. is the third largest drug delivery company in the United States. The company is primarily focused on research and development of drug delivery technologies for pharmaceutical products. Its drug delivery technologies include OraSolv(R)and DuraSolv(R) orally disintegrating tablet (ODT), Lyoc(R), Microsolv(R), OraVescent(R), and OTC(R) (oral transmuscosal). Cephalon currently manufactures the following products in the U.S. that use CIMA drug delivery technology: FENTORA(R) (fentanyl buccal tablet) [C-II] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II].
In addition, eight prescription and three over-the-counter products are distributed globally by its pharmaceutical partners. For more information please visit www.cimalabs.com.
About Cephalon, Inc.
Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of many unique products in three core therapeutic areas: central nervous system, pain, and oncology. A member of the Fortune 1000 and the S&P 500 Index, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. The company's European headquarters are located in Maisons-Alfort, France.
The company's proprietary products in the U.S. include: AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules), TREANDA(R) (bendamustine hydrochloride) for Injection, FENTORA(R), PROVIGIL(R) (modafinil) Tablets [C-IV], TRISENOX(R) (arsenic trioxide) injection, GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(R) (armodafinil) Tablets [C-IV] and ACTIQ(R). The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1-800-896-5855.
In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding the future strength and growth of Cephalon's drug delivery business, anticipated scientific progress on its research programs, development of potential pharmaceutical products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, sales and earnings guidance, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.
|SOURCE Cephalon, Inc.|
Copyright©2009 PR Newswire.
All rights reserved